Genprex (GNPX) Competitors $0.26 -0.02 (-5.43%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. SRZN, OKUR, GBIO, CVKD, EGRX, DARE, BCAB, GDTC, TPST, and QNTMShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Surrozen (SRZN), OnKure Therapeutics (OKUR), Generation Bio (GBIO), Cadrenal Therapeutics (CVKD), Eagle Pharmaceuticals (EGRX), Daré Bioscience (DARE), BioAtla (BCAB), CytoMed Therapeutics (GDTC), Tempest Therapeutics (TPST), and Quantum Biopharma (QNTM). These companies are all part of the "pharmaceutical products" industry. Genprex vs. Surrozen OnKure Therapeutics Generation Bio Cadrenal Therapeutics Eagle Pharmaceuticals Daré Bioscience BioAtla CytoMed Therapeutics Tempest Therapeutics Quantum Biopharma Genprex (NASDAQ:GNPX) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment. Do insiders and institutionals hold more shares of GNPX or SRZN? 14.1% of Genprex shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 8.5% of Genprex shares are held by insiders. Comparatively, 45.2% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer GNPX or SRZN? Surrozen has a consensus price target of $38.50, indicating a potential upside of 395.18%. Given Surrozen's stronger consensus rating and higher probable upside, analysts plainly believe Surrozen is more favorable than Genprex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, GNPX or SRZN? Genprex has higher earnings, but lower revenue than Surrozen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenprexN/AN/A-$30.86MN/AN/ASurrozen$11.64M5.72-$43.04M-$24.96-0.31 Which has more volatility & risk, GNPX or SRZN? Genprex has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Does the MarketBeat Community favor GNPX or SRZN? Genprex received 192 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 65.25% of users gave Genprex an outperform vote while only 31.82% of users gave Surrozen an outperform vote. CompanyUnderperformOutperformGenprexOutperform Votes19965.25% Underperform Votes10634.75% SurrozenOutperform Votes731.82% Underperform Votes1568.18% Is GNPX or SRZN more profitable? Surrozen's return on equity of -120.51% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets GenprexN/A -409.48% -269.17% Surrozen N/A -120.51%-54.68% Does the media favor GNPX or SRZN? In the previous week, Surrozen had 3 more articles in the media than Genprex. MarketBeat recorded 4 mentions for Surrozen and 1 mentions for Genprex. Genprex's average media sentiment score of 0.00 beat Surrozen's score of -0.19 indicating that Genprex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genprex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Surrozen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySurrozen beats Genprex on 10 of the 14 factors compared between the two stocks. Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.35M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E RatioN/A9.0426.7819.69Price / SalesN/A253.23386.97118.34Price / CashN/A65.8538.2534.62Price / Book0.056.406.744.50Net Income-$30.86M$143.98M$3.23B$248.32M7 Day Performance11.06%1.90%1.49%-0.03%1 Month Performance16.53%4.01%11.47%12.72%1 Year Performance-88.95%-3.00%16.57%7.38% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex0.921 of 5 stars$0.26-5.4%N/A-88.2%$7.35MN/A0.0020SRZNSurrozen2.9921 of 5 stars$8.00-4.2%$38.50+381.3%-24.7%$26.25M$10.66M-0.3280OKUROnKure Therapeutics2.9271 of 5 stars$1.95+1.6%$32.33+1,558.1%N/A$26.20MN/A-0.16N/AInsider TradeGap DownGBIOGeneration Bio3.272 of 5 stars$0.39+8.4%$7.33+1,778.4%-88.4%$26.16M$19.89M-0.18150Negative NewsHigh Trading VolumeCVKDCadrenal Therapeutics2.5318 of 5 stars$13.38-7.4%$32.00+139.2%N/A$25.96MN/A-2.004Analyst RevisionEGRXEagle PharmaceuticalsN/A$1.99+4.7%N/A-62.2%$25.84M$257.55M0.00100Gap DownDAREDaré Bioscience1.3942 of 5 stars$2.88-1.0%$24.00+733.3%-43.3%$25.49M$9,784.00-4.8830BCABBioAtla2.012 of 5 stars$0.43+0.6%$6.00+1,288.2%-83.6%$25.24M$11M-0.2560Gap DownGDTCCytoMed Therapeutics1.5896 of 5 stars$2.30+3.8%$5.00+117.0%+2.9%$25.21M$69,501.000.00N/AGap UpTPSTTempest Therapeutics1.9612 of 5 stars$6.87+5.9%$30.00+336.7%-85.6%$25.11MN/A-4.4920Analyst RevisionQNTMQuantum BiopharmaN/A$9.12+0.6%N/AN/A$24.68MN/A-0.59N/ANews Coverage Related Companies and Tools Related Companies SRZN Competitors OKUR Competitors GBIO Competitors CVKD Competitors EGRX Competitors DARE Competitors BCAB Competitors GDTC Competitors TPST Competitors QNTM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GNPX Stock Free GNPX Stock Alerts